Volume 129, Issue 4, 2022-4-1Pages A3-e41

Articlesinthisissue:

1. EditorialBoard

2. Contents

3. ThisIssueataGlance

4. ASimpleVistaenEsteNúmero

5. 期刊一览

6. Abstracts

7. ThePassingoftheTorch

8. TheEconomicBurdenofVisionLossandBlindnessintheUnitedStates

9. MultimodalImagingandHistopathologyFeaturesofaCornealKeloid

10. EfficacyandSafetyofOC-01(VareniclineSolution)NasalSprayonSignsandSymptomsofDryEyeDisease

11. ImmuneKeratitisHeraldsHLA-B27AssociatedPeripheralSpondyloarthropathy

12. Patient-ReportedSymptomsDemonstratinganAssociationwithSeverityofVisualFieldDamageinGlaucoma

13. RacialandSocioeconomicDifferencesinEyeCareUtilizationamongMedicareBeneficiarieswithGlaucoma

14. ExtrascleralExtensionfromChoroidalMelanomaDiagnosedonDopplerUltrasound

15. AssociationoftheCYP39A1G204EGeneticVariantwithIncreasedRiskofGlaucomaandBlindnessinPatientswithExfoliationSyndrome

16. ExuberantScleralCalcificationfromSecondaryHyperparathyroidism

17. CataractSurgeryandtheRiskofDevelopingLateAge-RelatedMacularDegeneration

18. Chromosome3and8qAberrationsinUvealMelanomaShowGreaterImpactonSurvivalinPatientswithLightIrisversusDarkIrisColor

19. AddingtheCancerGenomeAtlasChromosomeClassestoAmericanJointCommitteeonCancerSystemOffersMorePrecisePrognosticationinUvealMelanoma

20. TeprotumumabEfficacy,Safety,andDurabilityinLonger-DurationThyroidEyeDiseaseandRe-treatment

21. OrbitalRadiationforThyroidEyeDisease

22. DisparitiesinSelf-ReportedDifficultySeeingintheUnitedStates

23. RetinalDisplacementafterPneumaticRetinopexyversusVitrectomyforRhegmatogenousRetinalDetachment(ALIGN)

24. EmmetropizationduringEarlyChildhood

25. Physician-IndustryFinancialRelationships,KeyOpinionLeaderStatus,andProgramVisibility

26. Corrigendum

27. Re:Xiongetal.:MultimodalmachinelearningusingvisualfieldsandperipapillarycircularOCTscansindetectionofglaucomatousopticneuropathy(Ophthalmology.2022;129:171-180)

28. Reply

29. Zafaretal.:EndophthalmitisratesamongMedicarebeneficiariesundergoingcataractsurgerybetween2011and2019(Ophthalmology.2022;129:250-257)

30. Reply